Reports Q4 revenue $354M, consensus $342.33M. “2023 was another stellar year at Lantheus, during which the Company delivered record revenues, earnings, cash flows and patient impact as we continued to advance our position as the leading radiopharmaceutical-focused company,” said Mary Anne Heino, CEO of Lantheus. “We are entering 2024 on a strong foundation and will continue to leverage our deep expertise in radiopharmaceuticals and our significant capital resources to advance and expand our pipeline.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LNTH:
- Is LNTH a Buy, Before Earnings?
- Lantheus announces collaboration with NIA-sponsored study called CLARiTI
- Lantheus announces collaboration with a NIA-sponsored study called CLARiTT
- Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
- Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
